Wall Street analysts predict that Uniqure NV (NASDAQ:QURE) will post sales of $3.37 million for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Uniqure’s earnings, with the lowest sales estimate coming in at $3.00 million and the highest estimate coming in at $3.60 million. Uniqure reported sales of $2.26 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 49.1%. The firm is scheduled to report its next earnings results on Wednesday, November 7th.
According to Zacks, analysts expect that Uniqure will report full-year sales of $15.76 million for the current financial year, with estimates ranging from $12.50 million to $29.00 million. For the next year, analysts expect that the firm will post sales of $14.92 million per share, with estimates ranging from $10.00 million to $25.40 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Uniqure.
Uniqure (NASDAQ:QURE) last issued its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.04. Uniqure had a negative return on equity of 72.12% and a negative net margin of 677.98%. The company had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $3.37 million.
A number of equities analysts recently issued reports on the company. HC Wainwright set a $42.00 target price on Uniqure and gave the stock a “buy” rating in a report on Thursday, August 23rd. Cantor Fitzgerald set a $58.00 price target on Uniqure and gave the company a “buy” rating in a research report on Thursday, August 23rd. Cowen reissued a “buy” rating on shares of Uniqure in a research report on Monday, August 13th. BidaskClub raised Uniqure from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 9th. Finally, Janney Montgomery Scott reissued a “buy” rating on shares of Uniqure in a research report on Wednesday, August 8th. Two analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $44.89.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QURE. Quantbot Technologies LP raised its position in Uniqure by 3,972.6% in the 1st quarter. Quantbot Technologies LP now owns 5,498 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 5,363 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Uniqure by 276.5% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,400 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 4,700 shares during the last quarter. Financial Gravity Wealth Inc. purchased a new stake in shares of Uniqure during the 1st quarter valued at $177,000. Gagnon Securities LLC purchased a new stake in shares of Uniqure during the 2nd quarter valued at $209,000. Finally, Jane Street Group LLC purchased a new stake in shares of Uniqure during the 1st quarter valued at $224,000. 59.32% of the stock is owned by institutional investors and hedge funds.
Shares of QURE traded down $1.34 during trading hours on Friday, reaching $38.56. The stock had a trading volume of 144,000 shares, compared to its average volume of 349,596. Uniqure has a 12 month low of $8.22 and a 12 month high of $43.23. The company has a quick ratio of 8.36, a current ratio of 8.36 and a debt-to-equity ratio of 0.06. The stock has a market cap of $1.53 billion, a P/E ratio of -13.13 and a beta of 0.22.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Further Reading: Outstanding Shares, Buying and Selling Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.